Interest in this field has been sparked in recent years at least in part due to discovery of both VDRs and vitamin D-metabolizing enzymes in numerous cell types, highlighting a role for this molecule in non-classical target tissues 1 . In cancer cells for instance, calcitriol treatment regulates the expression of genes involved in cell cycle regulation, apoptotic signaling, differentiation, and nutrient metabolism [5] [6] [7] . A major limitation in vitamin D-based chemotherapy is the need for supra-physiological doses to achieve substantial anti-tumor effects 6 . Such doses lead to hypercalcemia, hampering their clinical utility. To circumvent this obstacle, non-calcemic vitamin D analogs have been developed, and several have made the way to
Vitamin D deficiency is a global pandemic that affects approximately one billion people worldwide 1 . This phenomenon has broad implications since accumulating evidence has demonstrated that deficiency in this vitamin increases the predisposition to a myriad of chronic diseases, such as cardiovascular disease and cancer 1, 2 . The human body can produce 7-dehydrocholesterol (a provitamin), which in the skin is converted by UV light to previtamin D 3 and further to vitamin D 3 . For the biosynthesis of its active form, vitamin D 3 undergoes two hydroxylation steps, the first occurring in the liver, yielding 25-hydroxyvitamin D [25(OH)D], which is the most reliable biomarker for vitamin D status in humans 1 . The second hydroxylation step takes place in the kidneys, producing 1,25(OH)2D (also known as calcitriol), which then binds to the nuclear vitamin D receptor (VDR), eliciting major changes in gene expression patterns in target cells 1 . Cytochrome P450 (CYP) 2R1 (CYP2R1) has been previously shown to be a major, although not exclusive vitamin D-25-hydroxylase 3 , whereas CYP27B1 is known to be the 25(OH)D-1-hydroxylase 1 . Moreover, levels of both 25(OH)D and 1,25(OH)2D are feedback regulated, by the 25(OH)D-24-hydroxylase CYP24A1 4 . Interest in this field has been sparked in recent years at least in part due to discovery of both VDRs and vitamin D-metabolizing enzymes in numerous cell types, highlighting a role for this molecule in non-classical target tissues 1 . In cancer cells for instance, calcitriol treatment regulates the expression of genes involved in cell cycle regulation, apoptotic signaling, differentiation, and nutrient metabolism [5] [6] [7] . A major limitation in vitamin D-based chemotherapy is the need for supra-physiological doses to achieve substantial anti-tumor effects 6 . Such doses lead to hypercalcemia, hampering their clinical utility. To circumvent this obstacle, non-calcemic vitamin D analogs have been developed, and several have made the way to (2019) 9:4616 | https://doi.org/10.1038/s41598-019-40851-9 www.nature.com/scientificreports www.nature.com/scientificreports/ the clinic, such as maxacalcitol and paricalcitrol, which are both used to treat secondary hyperparathyroidism 8 . Furthermore, recent genome-wide association studies have identified single-nucleotide polymorphisms (SNPs) in genes encoding proteins involved in vitamin D synthesis, transport, and metabolism that influence vitamin D status in humans 9, 10 . This is of major importance in determining subject-specific response to vitamin D supplementation, since different subjects possessing differing sets of SNPs would require varying doses of vitamin D compounds to elevate circulatory 25(OH)D levels to a desirable range, or to elicit specific biological effects. Therefore, reliable experimental systems are in demand to address these issues.
One category of in vitro models, which could address these issues is "organ-on-chip", which are microfluidic platforms that aim to closely resemble different tissue types. By now, multiple organ-on-chip systems have been developed, reviewed in [11] [12] [13] [14] [15] . Data have shown that culturing cells in microfluidic environments confers several advantages including enhanced cellular functionality. For example, hepatocytes cultured ex vivo quickly de-differentiate and lose their specific hepatic function 16, 17 , whereas cells cultured in microfluidic platforms maintained the functionality of multiple CYP enzymes 18 . Additionally, CYP expression as well as albumin uptake of renal tubular epithelial cells in microfluidic setups are reported to be closer to their physiological counterparts 19, 20 . Early work, which include studies by Koebe et al. and Ma et al. 21, 22 , has shown in vitro metabolism of drugs using mono-hepatocyte cultures. In case of the former, a hepatocyte bioreactor was combined with a microphysiometer system to assess extracellular acidification rate observed with hepatic metabolism. The latter study described a two-layered device where drug metabolite characterization and metabolism-induced cytotoxicity could be performed simultaneously. Studies utilizing microfluidic setups aiming to mimic tissue-tissue interactions include that of Choucha-Snouber et al., as well as our recent study 23, 24 . In both studies, two-compartment devices were used to illustrate nephrotoxicity exhibited upon hepatic metabolism of a molecule.
We have also illustrated the potential use of microfluidic devices for continuous monitoring of CYP activity in living cells 25 and the use of 3D multilayer platforms to mimic liver lobule 26 . In a more complex 3D based system, Weber et al. showed the recapitulation of proximal tubule microenvironment and functions, the secretory transport of organic solutes and the metabolism of 25(OH)D3 27 . We therefore proposed that such multi-compartment microfluidic platforms may be adopted in vitamin D research for various applications, including investigating the effect/functionality of SNPs in the vitamin D pathway on the metabolism/bio-activation of the parent molecule and novel vitamin D prodrugs, as well as to study the influence of different dietary nutrients and xenobiotics on vitamin D metabolism. To investigate such hypothesis, we employed a custom two-compartment microfluidic chip, and seeded the first compartment with HepG2 cells, and the second with RPTEC cells, to mimic sequential hepatic and renal vitamin D metabolism, respectively. We postulated that this setup would enable cells to produce and release vitamin D metabolites, namely 25(OH)D and 1,25(OH)2D, into the eluate, which could then be applied on target cells to investigate the metabolites' biological activities. In the current study, HL-60 (acute myeloid leukemia) cells were used to monitor the pro-differentiation effects of bioactive vitamin D, and thus provide evidence of the ability of the system to metabolize the vitamin (Fig. 1) .
Results
Functionality of the two-compartment liver-kidney chip design and demonstration of fluid dynamics. A two-chamber microfluidic platform was used. The individual chambers of the two-compartment microfluidic platform exhibited a length of 14,28 mm, a width of 5 mm, and a total volume of 36 µL. The two compartments were connected by a 150 µm narrow channel ( Fig. 2A) . The cultivation areas in the chambers are surrounded by guidance barriers which shield the cell culture area from the high shear rate of the fluidic flow and in addition serve as an air bubble trap (Fig. 2B,C) 
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. Using our previously reported seeding protocol 23 , each chamber could be seeded individually, which allowed distinct separation of the liver and kidney cells in the individual (Fig. 2D ). Cell culture areas were coated with 0.4% Collagen solution to ensure ECM formation as previously reported 17, 28 . Microscopical investigation of the cells in the compartments revealed confluent monolayers with sporadic multilayer formation (Fig. 2E ). After three days in dynamic culture, cellular viability was as high as 97.2% ± 2.2% and 97.8 ± 1.3% for HepG2 and RPTEC cells, respectively (Fig. 2G) .
The fluid dynamics of the chip were analyzed using the flow simulation software COMSOL Multiphysics, as previously reported 26 . The applied flow rate of 20 µL/h matched the simulated one. This low flow rate was used to facilitate the metabolic process, since our system was employed mono-directionally with no re-circulation. Flow velocity and shear rate were found to be highest in the narrow inlet/outlet as well as in the connection between the chambers. Within the cell culture area, low shear rate (0.05 Pa) and velocity was detected (Fig. 2F) .
We then evaluated the functionality of liver cells by measuring albumin production, and observed a constant albumin secretion during the culture period, declining levels as previously reported for static systems 23, 26 were not detected (Fig. 2H) . Uptake of FITC-Albumin was investigated as a marker for kidney cell activity 23 . Significant increase in the uptake was found under fluidic flow, compared to static culture (Fig. 2I) . Additionally, we investigated the effect of on-chip cultivation on the mRNA expression levels of vitamin D-metabolizing CYPs (CYP2R1, CYP27B1, CYP24A1) in RPTEC and HepG2 cells, and compared them to that of cells maintained in static culture conditions. Indeed, expression levels of these enzymes were found to be significantly induced with on-chip cultivation (Fig. 2J ). This is in line with our previous observation that the basal mRNA expression levels of various CYPs are induced with on-chip cultivation 23 . We further investigated the epithelial behavior of RPTEC cells by comparing the mRNA expression of Occludin, E-Cadherin and ZO-1 for cells cultured under static and under microfluidic conditions and observed enhanced expression of these markers with on-chip cultivation ( Supplementary Fig. 1 ). Altogether, these results clearly highlight the advantages the microfluidic setup imparts on cellular functions.
The eluate of vitamin D3-supplied liver-kidney chips induces differentiation of HL60 cells more potently than the parent molecule. Among the known anti-tumor effects mediated by 1,25(OH)2D3 is
its ability to induce differentiation in multiple tumor types, such as prostate, breast, and myeloid leukemia cells 2 .
To investigate the possibility that the liver-kidney microfluidic chip metabolizes vitamin D3 into its bioactive form, we continuously introduced medium containing either vitamin D3 (20 µM final concentration) or DMSO at a flow rate of 20 µL/h, for a period of 24 h (Fig. 3A) . After passage through the chip the eluted medium was collected and used to treat HL60 cells for 24 h. Total RNA was then isolated from cells, and mRNA expression levels of various differentiation markers, including CD11b, CD14, osteopontin, and parvalbumin, were assessed using RT-qPCR. In parallel, to provide suitable controls for comparisons, HL60 cells were treated with the different vitamin D3 metabolites-25(OH)D3 (2 µM), and 1,25(OH)2D3 (100 nM)-as well as vitamin D3, under standard treatment conditions. HL60 cells treated with the eluate of vitamin D3-treated chips exhibited enhanced mRNA expression of all investigated differentiation markers, compared to cells treated with medium eluted from DMSO-treated chips. Moreover, cells treated with the eluted medium of vitamin D3-treated chips exhibited higher expression levels for all investigated genes in comparison to reference treatment with vitamin D3, indicating metabolic transformation. Further comparison to treatments of HL-60 cells with either 25(OH)D3 or 1,25(OH)2D3 under standard conditions, revealed a mostly higher induction of differentiation markers in cells treated with the medium eluate of the vitamin D3-feeded liver-kidney chip, indicating the presence of one or more vitamin D metabolites in the eluate of treated chips (Fig. 3B) .
To verify these observations, we also analyzed the presence of differentiation markers on the protein level, using the cell surface markers CD11b and CD14. HL60 cells cultivated in DMSO-supplied chip eluate did not exhibit statistically significant differences in protein expression of these differentiation markers compared to cells cultivated in standard DMSO-treated medium. However, treatment with vitamin D3-containing chip eluate led to significantly higher protein expression of CD11b and CD14 in comparison to DMSO-treated cells, DMSO-treated chip eluate, as well as compared to standard treatments with either vitamin D3 or 1,25(OH)2D3 (Fig. 3C) .
Based on observations obtained in previous studies 23 , 29 , we postulated that on-chip cultivation may have led to an increased half-life of vitamin D3 metabolites due to the continuous production and secretion of albumin by HepG2 cells (Fig. 2H) , which may have led to the more sustained induction in differentiation markers compared to standard treatments performed in serum free medium. To investigate this hypothesis, we treated HL60 cells with 1,25(OH)2D3 (100 nM) and different concentrations of bovine serum albumin (BSA; including the concentration of albumin found in the HepG2 chip eluate Fig. 2H ). We did not observe significant differences in the regulation of expression of the different target genes by 1,25(OH)2D3 with different BSA concentrations ( Supplementary Fig. 2) . Therefore, the enhanced induction in the expression of these genes with the chip eluate may be due to other factors, such as the presence of different vitamin D metabolites in the eluate, or the secretion of factors by the liver and/or kidney chambers in response to vitamin D3 in the medium that may have led to the potentiated induction in expression.
under www.nature.com/scientificreports www.nature.com/scientificreports/ To investigate the necessity of both the liver and kidney cells in metabolizing vitamin D3, we seeded the two chip compartments with only HepG2 cells (liver-liver) and with HepG2-RPTEC (liver-kidney) (Fig. 3D) , and performed DMSO and vitamin D3 treatments as described earlier, after which the eluate was collected and used to treat HL-60 cells. The mRNA expression levels of differentiation markers, except CD11b, were more potently induced by the liver-kidney chip (Fig. 3E) , illustrating the distinctive effect of consecutive metabolism.
We further investigated on the effect of the close proximity of the liver-kidney system and the effect of the microfluidic flow and compared the induction of the differentiation markers for cells treated with static supernatant of HepG2 cells, static supernatant of HepG2-RPTEC cells and the chip eluate. For the static condition, medium was aspirated after 24 hours and put on HL60 cells for the HepG2 and on RPTEC cells for additional 24 hours for the HepG2. The results indicate that for all four markers, induction was highest using the chip eluate, in case of CD11b slight induction was also observed using static treatments (see Supplementary Fig. 3 ).
Treatment with the chip eluate regulates CYP expression in target tissues. Since we observed a clear induction in the expression of vitamin D metabolizing CYPs with on-chip cultivation, we postulated that on-chip treatment may also lead to altered CYP regulation compared to standard treatments, which could explain the differential regulation of differentiation markers observed. www.nature.com/scientificreports www.nature.com/scientificreports/ Therefore, we investigated the changes in mRNA expression patterns of the various CYPs involved in vitamin D3 metabolism in response to on-chip treatment, and compared them with those observed in cells treated under standard cell culture conditions. Medium containing either DMSO or vitamin D3 (final concentration 20 µM) was continuously introduced (flow rate: 20 µL/h) to chips only containing HepG2 cells for a period of 24 hours (reaching a final volume of 480 µL). A similar setup was repeated with RPTEC-seeded chips, however an additional treatment condition was included, in which chips were fed culture medium eluted from chips containing either DMSO-or vitamin D3-treated HepG2 cells (Fig. 4A) . Total RNA was then extracted from chips and changes in mRNA expression of the different CYPs were investigated using RT-qPCR. Furthermore, the same cell lines were treated for 24 hours with vitamin D3 (20 µM) and its metabolites-25(OH)D3 (2 µM), and 1,25(OH)2D3 (100 nM)-in static conditions, and changes in CYP mRNA expression levels were investigated (Fig. 4B) .
Similar and disparate effects on the mRNA expression of the investigated CYPs between HepG2 cells treated in static conditions with various vitamin D3 molecules and on-chip treated cells were observed. With regards to CYP24 A1 regulation, all treatments independent of culture method were found to induce mRNA levels. However, on-chip treated HepG2 cells exhibited comparable CYP24A1 mRNA expression to cells treated with either vitamin D3 metabolite in static conditions, but significantly higher levels compared to those treated with vitamin D3. Similarly, CYP2R1 induction in HepG2 cells treated on-chip was found to be more significant than that observed in cells treated with either the parent or the active molecule, however in line with that observed with 25(OH)D3 treatment. Regulation of CYP27B1 on the other hand was found to be similar in cells independent of culture and treatment conditions (Fig. 4B upper row) .
RPTEC cells treated with vitamin D3-containing medium eluted from HepG2 cells were found to express significantly different CYP24A1 and CYP2R1 mRNA levels compared to cells treated with either vitamin D3 metabolite in static conditions. Interestingly, looking at the same genes in RPTEC cells, on chip culture treated directly with vitamin D3 exhibited significantly different mRNA levels compared to chip cultures treated with vitamin D3-containing HepG2 eluate, indicating the presence of metabolic products in the HepG2 eluate. With regards to CYP27B1 mRNA levels, statistically insignificant differences were observed between chips treated with vitamin D3-containing eluent and those treated with vitamin D3, as well as compared to cells exposed to the various treatments in static conditions (Fig. 4B) .
Detection of vitamin D3 metabolite(s) in the liver-kidney chip eluate.
In view of these data, we aimed to investigate whether vitamin D3 metabolites were produced and secreted by cells in the microfluidic chip. To this end, we performed LC-MSMS to assess the presence of either vitamin D3, 25(OH)D3, 1(OH)D3, or 1,25(OH)2D3 in the eluted medium of treated chips. A previously described method was used 30 , with minor modifications, to achieve base-line separation of all analytes of interest, after which the fragmentation patterns of the standards were determined. Noteworthy is that both the parent molecule and the bioactive form exhibit short half-lives, in contrast to 25(OH)D 31 , which is also reflected in the use of blood plasma levels of this metabolite to determine the vitamin D status in humans.
For the analytical determination of metabolites the same treatment protocol as described in the previous section (illustrated in Fig. 4A ) was used, and vitamin D metabolites were extracted from the eluted medium. A peak corresponding to 25(OH)D3 was detected in the medium eluted from both the liver-liver and the liver-liver-kidney-kidney chips (Fig. 5A ) Neither vitamin D3 nor 1,25(OH)2D3 were detected in the chip eluates, possibly due to either their short half-life or technical limitations (e.g. levels below limit of detection of the chromatographic method, or low extraction yield) (Fig. 5A) .
The obtained MS spectra of the peaks were compared to the ones of standard substances, and an accurate match of masses was observed, confirming the metabolism of vitamin D3 to 25(OH)D 3 ( Supplementary Fig. 4 ) Based on the comparison with the standard calibration curve, a lower concentration of 25(OH)D3 was found in the eluate of the liver-liver-kidney-kidney chip compared to the concentration in the eluate of the liver-liver chip (1.26 µM vs 1.48 µM 25(OH)D3) ( Supplementary Fig. 4) .
We then decided to revisit the discrepancy in the induction of the differentiation markers when comparing the chip eluate and reference vitamin D3 metabolites (Fig. 3B,C) . HL60 cells were treated with various concentrations of 25(OH)D3 and the mRNA and protein expression levels of CD14 and CD11b were analyzed using RT-qPCR and FACS, respectively (Fig. 5B) . To our surprise even though 25(OH)D3 clearly induces the expression of the differentiation markers, the tested concentrations had no major effects on the expression level in our experiments (Fig. 5C,D) . Although only 25(OH)D3 could be detected analytically, the biological effects of the eluate clearly demonstrate the capacity of our system to metabolize and secrete activated vitamin D3.
Discussion
A plethora of in vitro and preclinical studies have demonstrated vitamin D effects beyond bone mineralization. In oncology, data illustrate the ability of this molecule to induce apoptosis and differentiation, modulate metabolism, as well as inhibit proliferation and metastasis 2, [5] [6] [7] 32 . However, several issues complicate the translation of these findings to the clinic, including the hypercalcemia associated with high calcitriol doses 8 , as well as the presence of SNPs in the vitamin D pathway that influence vitamin D status and possibly response to supplementation 9, 10 . Moreover, the inconclusiveness of recent vitamin D randomized-controlled trials evaluating the molecule's anti-cancer potential has been attributed to the lack of increase in serum 25(OH)D levels in response to supplementation 33 , which may be due to different vitamin D metabolizing efficiencies of the recruited subjects. We propose that the experimental setup described here enables comprehensive tackling of these issues, since cell lines genetically modified to harbor common variants in vitamin D metabolizing genes may be used to investigate the functionality/effect of such mutations on vitamin D metabolism, as well as that of novel vitamin D pro-drugs. Additionally, the system could be used to study the impact of different drugs and nutrients on vitamin D metabolism, which may influence the outcomes of supplementation. www.nature.com/scientificreports www.nature.com/scientificreports/ Here we demonstrate the use of our two-compartment microfluidic platform for mimicking vitamin D3 metabolism in vitro. We show that passing vitamin D3 through two consecutive chambers, resembling the liver and kidneys, yields metabolic products that induce anti-cancer effects in acute myeloid leukemia cells, in a manner similar to that observed with the bio-active form of vitamin D3. Finally, we analyzed the differentiation of acute myeloid leukemia cells (HL60 cells), as a model for vitamin D3 anti-cancer activity.
Indeed, medium eluted from chips initially treated with vitamin D3 was found to induce the expression of differentiation markers in HL-60 cells in a manner more potent than that observed with standard vitamin D3 treatment. The changes observed were similar to that obtained by calcitriol treatment, indicating the possible occurrence of complete metabolic activation. Additionally, comparing the mRNA expression of relevant CYPs between cells seeded on-chip versus standard cell culture dishes highlights the improved metabolic profile in the micro-fluidic setting. Moreover, we detected metabolic products of vitamin D3 using HPLC/MS. Altogether, our data signify that the described microfluidic chip can be used to mimic vitamin D3 metabolism in vitro.
First we illustrate the efficient and complete metabolism of vitamin D3 by cells in the microfluidic device, and demonstrate differential cellular responses between on-chip and static treatments (Fig. 3B) . We postulate that these discrepancies may be explained by a number of factors observed in this study as well as previously reported results by others 23, 26, 34 , including enhanced albumin secretion and uptake (see Fig. 2H and I) , as well as altered CYP expression in response to shear stress (Fig. 2J) . Additionally, gradual introduction of culture medium containing vitamin D3 to cells in the microfluidic device, as opposed to single high volume treatments performed on cells cultured in static conditions, may have led to altered regulation of particular CYPs. For example, on-chip vitamin D3 treatments led to higher CYP24A1 mRNA levels in HepG2 cells in comparison with the same treatment in static conditions. Similarly, the altered regulation of CD11b and CD14 expression in HL-60 cells treated with vitamin D3-containing chip eluent compared to standard treatments was initially postulated to be the result of an extended half-life of the metabolites in the eluted medium, which was found to contain higher albumin levels compared to medium supernatant of static conditions. In such scenario, metabolic products released from chips would be less "free" and more "bound" to albumin-and vitamin D binding protein-enabling a slower, more sustained activation of differentiation markers in HL-60 cells compared to the rapid and potentially transient regulation seen with treatments performed in serum-free medium. However, we observed that increasing concentrations of BSA in the culture medium do no impact 1,25(OH)2D3's regulation of its target genes. Therefore, the enhanced induction in the expression of the investigated genes with the eluate treatment may be due to the secretion of factors by cells in the microfluidic chip that potentiate vitamin D's regulation of its target genes.
In conclusion, we propose that the experimental setup described in this report could be exploited in studies investigating the metabolism and activities of vitamin D, as well as other micronutrients and xenobiotics.
Materials and Methods
Cell culture. HepG2 cells, RPTEC cells and HL60 cells were obtained from ATCC (ATCC, Manassas, USA).
Before use in the microfluidic system cells were maintained following standard mammalian tissue culture protocols. In short, cells were maintained in T25 flasks (Corning, Kaiserslautern, Germany) in DMEM high glucose containing 10% fetal bovine serum and 1% Penicillin-Streptomycin (10.000 U/ml) (Gibco Thermo Fisher Scientific, Germany) in a conventional humidified tissue culture incubator at 37 °C and 5% CO 2 . As reported before 23 , cells were maintained at low passage number <7 and cells were split at confluencies of >85% using standard cell culture procedures.
Microfluidic system. A detailed characterization of the Chip design, the seeding pattern, the fluid dynamics and the applied fluidic propulsion system had been described previously 23 . For clarity a description of the main components of the system and parameters for cell seeding and cultivation are also provided here. The system is based on a two-chamber interconnected microfluidic chip, fabricated by ChipShop 23 . For microfluidic flow chips are connected with low pressure nEMESYS syringe pumps (Cetoni, Germany).
Cell seeding in microfluidic flow chips. Following the same procedure as previously described 23 , before seeding chambers of the microfluidic chips were coated with collagen for one hour at 37 °C using a 1:3 dilution of a 0.4% Collagen R solution (Serva, Germany) in PBS. The solution was then washed out and thoroughly removed using PBS. Subsequently HepG2 cells and RPTEC cells were seeded in the respective chambers at 6 × 10 5 cells, resulting in dense cell layer in each compartment (chamber). To ensure that cells did not mix between the chambers of the chip, an optimized seeding pattern was used 23 , After seeding, the two-chamber chips were placed in an incubator for 4 h. Then medium was replaced and cells seeded in the chips were further incubated overnight in static conditions (without flow) at 37 °C in humidified atmosphere, 5% CO 2 to ensure formation of a stable cell layer before introduction of medium flow 23 .
Culture conditions in microfluidic flow chips. Following the overnight incubation in static conditions microfluidic flow was applied using a constant microfluidic flow of 20 µL/h. For this, the low pressure nEMESYS syringe pump (Cetoni Germany) was set up in a combination with a 5.0 mL syringe and a H 1/4″-28 Tubing Connector (ILS, Germany). For coupling to the microfluidic chip PEEK tubing (inner diameter 1/32″) was used, and connected to chips with a miniLuer adapter (ChipShop, Jena) as described 23 . The unidirectional medium flow was applied via the HepG2 chamber providing a "liver to kidney" flow direction and the flow through (supernatant) was taken after medium also passed through the RPTEC chamber.
Microfluidic cell culture for metabolism studies. For metabolism analysis under fluidic conditions, HepG2 cells and RPTEC cells were cultured in microfluidic chip chambers at 37 °C with 5% CO 2 and supplied with DMEM high glucose without phenol red, and without adding fetal bovine serum or Penicillin-Streptomycin.
